IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas

Leukemia

Volumn 27, Issue 1, 2013, Pages 183-189

  Gachard, N ^a   Parrens, M ^b   Soubeyran, I ^c   Petit, B ^d   Marfak, A ^a   Rizzo, D ^a   Devesa, M ^a   Delage Corre, M ^d   Coste, V ^e   Laforet M P ^a   De Mascarel, A ^b   Merlio, J P ^f   Bouabdhalla, K ^g   Milpied, N ^g   Soubeyran, P ^c   Schmitt, A ^c   Bordessoule, D ^d   Cogne M ^a   Feuillard, J ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b EA 2406 CHU ^*  (France)

^c INSTITUT BERGONIÉ   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e GUI DE CHAULIAC HOSPITAL   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

immunoglobulin gene sequence; marginal zone lymphoma; MYD88

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; MYELOID DIFFERENTIATION FACTOR 88;

ARTICLE; CELL MATURATION; CELL STRUCTURE; CYTOLOGY; FLOW CYTOMETRY; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; LYMPH NODE; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; MARGINAL ZONE LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLEEN; WALDENSTROEM MACROGLOBULINEMIA;

FLOW CYTOMETRY; GENE REARRANGEMENT; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN M; IMMUNOGLOBULIN VARIABLE REGION; LYMPH NODES; LYMPHOMA, B-CELL, MARGINAL ZONE; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; PROGNOSIS; SPLENIC NEOPLASMS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84873568405     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.257     Document Type: Article

References (42)

1. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005; 106: 1831-1838.
2. Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005; 18: 57-68.
3. Berger F, Traverse-Glehen A, Felman P, Callet-Bauchu E, Baseggio L, Gazzo S et al. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity? Clin Lymphoma 2005; 5: 220-224.
4. Piris MA, Arribas A, Mollejo M. Marginal zone lymphoma. Semin Diagn Pathol 2011; 28: 135-145.
5. Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC. Press: Lyon, 2008.
6. Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 2007; 18: 346-350.
7. Thieblemont C, Davi F, Noguera ME, Briere J. Non-MALT marginal zone lymphoma. Curr Opin Hematol 2011; 18: 273-279.
8. Arcaini L, Lucioni M, Boveri E, Paulli M. Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease. Eur J Haematol 2009; 83: 165-174.
9. Rinaldi A, Mian M, Chigrinova E, Arcaini L, Bhagat G, Novak U et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood 2011; 117: 1595-1604.
10. Arribas JA, Campos-Martin Y, Gomez-Abad C, Algara P, Sanchez-Beato M, Rodriguez-Pinilla MS et al. Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood 2011; 119: e9-e21.
11. Craig VJ, Arnold I, Gerke C, Huynh MQ, Wundisch T, Neubauer A et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 2010; 115: 581-591.
12. Parrens M, Gachard N, Petit B, Marfak A, Troadec E, Bouabdhalla K et al. Splenic marginal zone lymphomas and lymphoplasmacytic lymphomas originate from B-cell compartments with two different antigen-exposure histories. Leukemia 2008; 22: 1621-1624.
13. Zibellini S, Capello D, Forconi F, Marcatili P, Rossi D, Rattotti S et al. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica 2010; 95: 1792-1796.
14. Warsame AA, Aasheim HC, Nustad K, Troen G, Tierens A, Wang V et al. Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly-and self-reactive antibodies with similar reactivity. Blood 2011; 118: 3331-3339.
15. Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S, Traverse-Glehen A et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia 2012; 26: 1638-1646.
16. Martin-Jimenez P, Garcia-Sanz R, Balanzategui A, Alcoceba M, Ocio E, Sanchez ML et al. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica 2007; 92: 635-642.
17. Walsh SH, Laurell A, Sundstrom G, Roos G, Sundstrom C, Rosenquist R. Lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation. Leuk Res 2005; 29: 729-734.
18. Sahota SS, Forconi F, Ottensmeier CH, Provan D, Oscier DG, Hamblin TJ et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002; 100: 1505-1507.
19. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004; 104: 2134-2142.
20. Treon SP, Xu L, Zhou Y, Liu X, Yang G, Cao Y et al. Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia. Blood, ed. American Society of Hematology Annual Meeting 2011; 118: (abstract 300).
21. Xu L, Sohani AR, Arcaini L, Hunter Z, Yang G, Zhou Y et al. A somatic variant in MYD88 (L265P) revealed by whole genome sequencing differentiates lymphoplasmacytic lymphoma from marginal zone lymphomas. Blood, ed. American Society of Hematology Annual Meeting 2011; 118: (abstract 261).
22. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
23. Yan Q, Huang Y, Watkins AJ, Kocialkowski S, Zeng N, Hamoudi RA et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 2012; 97: 595-598.
24. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317.
25. Smith LM, Sanders JZ, Kaiser RJ, Hughes P, Dodd C, Connell CR et al. Fluorescence detection in automated DNA sequence analysis. Nature 1986; 321: 674-679.
26. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008; 36: W503-W508.
27. Mollova S, Retter I, Mü ller W. Visualising the immune repertoire. BMC Syst Biol 2007; 1(Suppl 1): P30.
28. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000; 97: 10209-10213.
29. Chang B, Casali P. The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement. Immunol Today 1994; 15: 367-373.
30. Petit B, Chaury MP, Le Clorennec C, Jaccard A, Gachard N, Moalic-Judge S et al. Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica 2005; 90: 200-206.
31. Petit B, Parrens M, Soubeyran I, Costes-Martineau V, Gachard N, Boulin M et al. Among 157 marginal zone lymphomas, DBA.44(CD76) expression is restricted to tumour cells infiltrating the red pulp of the spleen with a diffuse architectural pattern. Histopathology 2009; 54: 626-631.
32. Traverse-Glehen A, Baseggio L, Salles G, Felman P, Berger F. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification. Curr Opin Oncol 2011; 23: 441-448.
33. McMaster ML, Caporaso N. Waldenstrom macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition. Br J Haematol 2007; 139: 663-671.
34. Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. Crit Rev Oncol Hematol 2008; 67: 172-185.
35. Harris NLJE, Stein H, Vardiman JW (eds)World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC. Press: Lyon, 2001.
36. Waldenström J. Kliniska metoder fö r påvusande av hyperproteinämi och deras praktiska värde fö r diagnostiken. Nordisk Med 1943; 20: 2288.
37. Dimopoulos MA, Chen C, Kastritis E, Gavriatopoulou M, Treon SP. Bortezomib as a treatment option in patients with Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk 2010; 10: 110-117.
38. Traverse-Glehen A, Davi F, Ben Simon E, Callet-Bauchu E, Felman P, Baseggio L et al. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica 2005; 90: 470-478.
39. Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001; 159: 253-261.
40. Camacho FI, Algara P, Mollejo M, Garcia JF, Montalban C, Martinez N et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003; 27: 762-771.
41. Meffre E, Davis E, Schiff C, Cunningham-Rundles C, Ivashkiv LB, Staudt LM et al. Circulating human B cells that express surrogate light chains and edited receptors. Nat Immunol 2000; 1: 207-213.
42. Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009; 206: 139-151.